PlumX Metrics
Embed PlumX Metrics

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment

Pharmaceutics, ISSN: 1999-4923, Vol: 15, Issue: 10
2023
  • 2
    Citations
  • 0
    Usage
  • 4
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

New Adenocarcinoma Study Findings Recently Were Reported by a Researcher at Sichuan University (Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment)

2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Investigators publish new report on adenocarcinoma. According to news

Review Description

Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest malignancies worldwide, is characteristic of the tumor microenvironments (TME) comprising numerous fibroblasts and immunosuppressive cells. Conventional therapies for PDAC are often restricted by limited drug delivery efficiency, immunosuppressive TME, and adverse effects. Thus, effective and safe therapeutics are urgently required for PDAC treatment. In recent years, hydrogels, with their excellent biocompatibility, high drug load capacity, and sustainable release profiles, have been developed as effective drug-delivery systems, offering potential therapeutic options for PDAC. This review summarizes the distinctive features of the immunosuppressive TME of PDAC and discusses the application of hydrogel-based therapies in PDAC, with a focus on how these hydrogels remodel the TME and deliver different types of cargoes in a controlled manner. Furthermore, we also discuss potential drug candidates and the challenges and prospects for hydrogel-based therapeutics for PDAC. By providing a comprehensive overview of hydrogel-based therapeutics for PDAC treatment, this review seeks to serve as a reference for researchers and clinicians involved in developing therapeutic strategies targeting the PDAC microenvironment.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know